Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Development of a new osmium-191: Iridium-191m radionuclide generator: Final report

Technical Report ·
OSTI ID:6708730
The use of iridium-191m (T/sub 1/2/ = 5s) for first-pass radionuclide angiography offers the potential advantages of lower patient radiation dose and the ability to obtain repeated studies without interference from the previously administered radioisotope. These potential advantages have been offset by the absence of satisfactory /sup 191/Os-/sup 191m/Ir generators. The goal of this project was, therefore, the development of an /sup 191/Os-/sup 191m/Ir generator that would be suitable for clinical use. This goal was first sought through modifications of an existing /sup 191/Os-/sup 191m/Ir generator design (i.e., changes in the ion exchange material and eluent) but these changes did not lead to the required improvements. A new approach was then undertaken in which different chemical forms of the /sup 191/Os parent were evaluated in prototype generators. The complex trans-dioxobisoxalatoosmate (VI) led to a generator with higher /sup 191m/Ir yield (25 to 30%/mL) and lower /sup 191/Os breakthrough (<5 x 10/sup -4/%) with a more physiologically compatible eluent than had been previously achieved. Toxicity studies were conducted on the eluate and an IND subsequently obtained. While this is not a final solution to the problem of developing a clinically acceptable /sup 191/Os-/sup 191m/Ir generator, the ''oxalate'' generator is the most significant improvement of the /sup 191/Os-/sup 191m/Ir generator to date and will be used in an expanded program of clinical studies. 16 refs., 16 tabs.
Research Organization:
Children's Hospital Corp., Boston, MA (USA)
DOE Contract Number:
AC02-82ER60084
OSTI ID:
6708730
Report Number(s):
DOE/ER/60084-6; ON: DE87007736
Country of Publication:
United States
Language:
English